Sustained viral response and hematological adverse events during chronic hepatitis C infection treatment.

about

Sustained viral response and hematological adverse events during chronic hepatitis C infection treatment.

Item

http://www.wikidata.org/entity/Q42554331

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Sustained viral response and h ...... patitis C infection treatment.

@en

Sustained viral response and h ...... patitis C infection treatment.

@nl

type

Item

label

Sustained viral response and h ...... patitis C infection treatment.

@en

Sustained viral response and h ...... patitis C infection treatment.

@nl

prefLabel

Sustained viral response and h ...... patitis C infection treatment.

@en

Sustained viral response and h ...... patitis C infection treatment.

@nl

P1476

Sustained viral response and h ...... patitis C infection treatment.

@en

P2093

Mona Isa

http://www.w3.org/2001/XMLSchema#string

Mortada El-Shabrawi

http://www.w3.org/2001/XMLSchema#string

P2860

Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment

Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy.

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin.

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection

Transmission of hepatitis C virus in Asia: past and present perspectives.

Future therapy of hepatitis C.

Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients.

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.

P304

122-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5812/HEPATMON.831

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224053090

http://www.w3.org/2001/XMLSchema#string

P698

22509190

http://www.w3.org/2001/XMLSchema#string

P932

3321320

http://www.w3.org/2001/XMLSchema#string